vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and United Maritime Corp (USEA). Click either name above to swap in a different company.

United Maritime Corp is the larger business by last-quarter revenue ($1.8M vs $1.8M, roughly 1.0× INVO Fertility, Inc.). United Maritime Corp runs the higher net margin — 59.6% vs -150.5%, a 210.1% gap on every dollar of revenue. United Maritime Corp produced more free cash flow last quarter ($-477.0K vs $-1.8M).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Navios Maritime Holdings Inc. is a multinational, vertically integrated seaborne shipping and logistics company focused on the transport and transshipment of drybulk commodities including iron ore, coal and grain.

IVF vs USEA — Head-to-Head

Bigger by revenue
USEA
USEA
1.0× larger
USEA
$1.8M
$1.8M
IVF
Higher net margin
USEA
USEA
210.1% more per $
USEA
59.6%
-150.5%
IVF
More free cash flow
USEA
USEA
$1.3M more FCF
USEA
$-477.0K
$-1.8M
IVF

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
IVF
IVF
USEA
USEA
Revenue
$1.8M
$1.8M
Net Profit
$-2.6M
$1.1M
Gross Margin
Operating Margin
-93.1%
Net Margin
-150.5%
59.6%
Revenue YoY
22.6%
Net Profit YoY
-62.2%
EPS (diluted)
$-0.77
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
USEA
USEA
Q3 25
$1.8M
$1.8M
Q2 25
$1.9M
Q1 25
$1.6M
Q4 24
$1.7M
Q3 24
$1.4M
Q2 24
$1.8M
Q1 24
$1.6M
Q4 23
$1.4M
Net Profit
IVF
IVF
USEA
USEA
Q3 25
$-2.6M
$1.1M
Q2 25
$-5.3M
Q1 25
$-17.4M
Q4 24
$-3.6M
Q3 24
$-1.6M
Q2 24
$-2.2M
Q1 24
$-1.6M
Q4 23
$-2.0M
Gross Margin
IVF
IVF
USEA
USEA
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Q4 23
33.0%
Operating Margin
IVF
IVF
USEA
USEA
Q3 25
-93.1%
Q2 25
-160.4%
Q1 25
-1042.1%
Q4 24
-202.0%
Q3 24
-90.7%
Q2 24
-100.9%
Q1 24
-95.7%
Q4 23
-109.2%
Net Margin
IVF
IVF
USEA
USEA
Q3 25
-150.5%
59.6%
Q2 25
-283.6%
Q1 25
-1060.1%
Q4 24
-211.3%
Q3 24
-113.8%
Q2 24
-122.2%
Q1 24
-101.3%
Q4 23
-144.4%
EPS (diluted)
IVF
IVF
USEA
USEA
Q3 25
$-0.77
$0.13
Q2 25
$-13.30
Q1 25
$-12.53
Q4 24
$14.86
Q3 24
$-15.11
Q2 24
$-22.39
Q1 24
$-7.55
Q4 23
$-59.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
USEA
USEA
Cash + ST InvestmentsLiquidity on hand
$19.7M
Total DebtLower is stronger
$2.0M
$49.5M
Stockholders' EquityBook value
$5.8M
$57.5M
Total Assets
$18.8M
$144.2M
Debt / EquityLower = less leverage
0.34×
0.86×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
USEA
USEA
Q3 25
$19.7M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Total Debt
IVF
IVF
USEA
USEA
Q3 25
$2.0M
$49.5M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
IVF
IVF
USEA
USEA
Q3 25
$5.8M
$57.5M
Q2 25
$2.6M
Q1 25
$3.3M
Q4 24
$12.7M
Q3 24
$-23.3K
Q2 24
$1.4M
Q1 24
$10.2K
Q4 23
$892.8K
Total Assets
IVF
IVF
USEA
USEA
Q3 25
$18.8M
$144.2M
Q2 25
$19.3M
Q1 25
$31.7M
Q4 24
$46.4M
Q3 24
$17.0M
Q2 24
$17.8M
Q1 24
$17.3M
Q4 23
$18.5M
Debt / Equity
IVF
IVF
USEA
USEA
Q3 25
0.34×
0.86×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
USEA
USEA
Operating Cash FlowLast quarter
$-1.8M
$-444.0K
Free Cash FlowOCF − Capex
$-1.8M
$-477.0K
FCF MarginFCF / Revenue
-101.6%
-26.1%
Capex IntensityCapex / Revenue
0.5%
1.8%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
USEA
USEA
Q3 25
$-1.8M
$-444.0K
Q2 25
$-1.7M
Q1 25
$-3.5M
Q4 24
$-617.4K
Q3 24
$-640.8K
Q2 24
$-1.5M
Q1 24
$-260.6K
Q4 23
$-714.9K
Free Cash Flow
IVF
IVF
USEA
USEA
Q3 25
$-1.8M
$-477.0K
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
Q1 24
$-310.3K
Q4 23
FCF Margin
IVF
IVF
USEA
USEA
Q3 25
-101.6%
-26.1%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
Q1 24
-19.7%
Q4 23
Capex Intensity
IVF
IVF
USEA
USEA
Q3 25
0.5%
1.8%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
4.6%
Q3 24
0.0%
Q2 24
3.0%
Q1 24
3.2%
Q4 23
Cash Conversion
IVF
IVF
USEA
USEA
Q3 25
-0.41×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons